Disease: Neoplasm, Residual ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Results show that both aGVHD and minimal residual disease (MRD) eradication did significantly affect TCR gamma/delta profile. 16249028 2006
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE To date, the main leukemia-specific DNA sequences used as PCR targets in detection of MRD are breakpoint fusion regions of chromosome translocations and junctional regions of rearranged immunoglobulin (Ig) or T-cell receptor (TcR) genes. 8255100 1993
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE A successful MRD detection approach requires a stable marker and for lymphoid leukemias clonal rearrangements of immunoglobulin (Ig) and T cell receptor (TCR) genes are commonly used. 11684274 2001
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements function as specific markers for minimal residual disease (MRD), which is one of the best predictors of outcome in childhood acute lymphoblastic leukemia (ALL). 20730889 2010
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. 15295608 2004
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. 16266899 2005
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE We show that MRD quantitation using clonal Ig/TCR rearrangements successfully assesses the risk in pediatric ALL patients undergoing allogeneic HSCT. 16521130 2007
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE With respect to the new methods of detecting minimal residual disease (MRD) in lymphoid malignancies utilizing PCR-mediated amplification of the junctional regions of TcR genes, our data indicate that this MRD-PCR analysis will generally be more sensitive if TcR-delta instead of TcR-gamma junctional-region-specific probes are used. 1837811 1991
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE MRD status was assessed in 43 patients by the detection of major rearrangements in TCR and Ig and the presence of chimeric mRNA. 23388549 2013
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Tumour-specific oligoprobes were developed against the single V1-J1 rearrangement of the delta T-cell receptor (TCR) gene in order to perform minimal residual disease (MRD) studies. 7669677 1995
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Crosslineage T-cell receptor delta (TCR delta) rearrangements are widely used as tumor markers for the follow up of minimal residual disease in childhood B-precursor acute lymphoblastic leukemia (ALL) by polymerase chain reaction (PCR). 7606000 1995
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE WT1 expression was not related to either MRD detection by IgH/TCR assays or to clinical leukemic relapse. 12796792 2003
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Several means of analyzing minimal residual disease (MRD) in leukemia involving the rearranged T cell receptor (TCR) gene have been described. 9111164 1997
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE A real-time PCR assay was applied for MRD quantification using LightCycler technology and the SYBR green fluorescent dye for detection of clone-specific Ig and TCR gene rearrangements as target sequences. 12384148 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Acute lymphoblastic leukemia (ALL) cells have unique rearranged immunoglobulin heavy chain (IgH), immunoglobulin light chain (IgK), and T-cell receptor (TCR) genes, which can be used as markers for clonality assay and evaluation of minimal residual disease. 24620952 2014
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE The present study aimed to examine whether monoclonal immunoglobulin heavy chain (IGH) or T-cell receptor (TCR) gene rearrangement in cell-free DNA (cfDNA) may be used for minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia (AML). 30008930 2018
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE The heterogeneity reported here in Ig and/or TcR gene rearrangement patterns at diagnosis and relapse might hamper polymerase chain reaction (PCR)-mediated detection of minimal residual disease (MRD) using junctional regions of rearranged Ig or TcR genes as PCR targets. 8161789 1994
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Direct sequence analysis of TCR V delta 2-D delta 3 rearrangements in common acute lymphoblastic leukaemia and application to detection of minimal residual disease. 8217823 1993
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE We evaluate whether molecular monitoring of minimal residual disease (MRD) using TCR delta (TCRD), TCR gamma (TCRG), and immunoglobulin H (IgH) gene rearrangements in the bone marrow (BM) is correlated with clinical events in ALL patients. 16247752 2005
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. 11896540 2002
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE These data provide insight into the immunobiological characteristics of Ig/TCR gene rearrangements in childhood precursor-B-ALL and form a useful basis for designing improved strategies for the identification and selection of MRD-PCR targets. 12970784 2003
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 GeneticVariation phenotype BEFREE Using IgH and TCR gamma gene rearrangements as gene markers, we detected minimal residual disease (MRD) by means of the polymerase chain reaction (PCR) and restriction analysis. 8735342 1996
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Incomplete T-cell-receptor delta (TCR-delta) rearrangements are widely used for detection of minimal residual disease in childhood acute lymphoblastic leukemia. 12860036 2003
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE We conclude that although Ig/TCR quantification is a reliable method for post transplant MRD detection, isolated positivities in Ig-based RQ-PCR systems at the time of intense B-cell regeneration must be viewed with caution to avoid the wrong indication of treatment. 18490915 2008
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Minimal residual disease was detected by polymerase chain reaction (PCR) with homo/heteroduplex analysis using consensus primers to IgH and TCR genes. 21774746 2012